NCT00227539View on ClinicalTrials.gov

Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

November 30, 2013

Conditions

Lung Cancer

Interventions

DRUG

cisplatin

DRUG

pemetrexed disodium

PROCEDURE

adjuvant therapy

PROCEDURE

therapeutic conventional surgery

RADIATION

fludeoxyglucose F 18

Trial Locations (2)

98195

University of Washington School of Medicine, Seattle

98109-1023

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00227539 - Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter